NEW YORK--(BUSINESS WIRE)--Emendo Biotherapeutics, a next-generation CRISPR company expanding the reach of gene editing therapeutics, will be presenting a poster at the annual American Society of Hematology conference in Atlanta, taking place December 11-14, 2021. The poster will present data from a CRISPR-based ex vivo strategy involving allele-specific excision of the mutant ELANE allele responsible for severe congenital neutropenia.
Poster Presentation: #3122 - Safe and Efficient Engraftment of CRISPR-based ELANE Mono-Allelic Knocked Out HSCs in Mice: Evidence for a Novel Treatment for ELANE Neutropenia
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Session Date and Time: Monday, December 13, 2021, 6:00 p.m - 8:00 p.m.
Location: Hall B5, Georgia World Congress Center
Presenter: Vahagn Makaryan
About Emendo Biotherapeutics
EmendoBio is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide EmendoBio with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit us at www.emendobio.com.
